NRx Pharmaceuticals’ investigational antidepressant has failed to reach statistical significance in reducing depression severity in a phase 2/3 trial, though the biotech is pressing forward to a registrational study with the belief that the candidate could eventually become a “paradigm-changing blockbuster drug.”
Macleods' Generic Lurasidone Hydrochloride Receives Receives Approval in the U.S.
Aurobindo's Generic Lurasidone Hydrochloride Receives Approval in U.S.
Alkem's Generic Lurasidone Hydrochloride Receives Approval in the U.S.
MSN's Generic Lurasidone HCL Receives Approval in the U.S.
Watson Labs Teva `s Generic Lurasidone Hydrochloride Receives Approval in US
Sumitomo Dainippon is set to pay $3 billion upfront to buy Roivant’s stake in five of its Vant startups. The deal could provide Dainippon with a series of new product launches to offset the loss of patent protection on bipolar depression drug Latuda.
Emcure Pharms Generic Lurasidone Hydrochloride Receives Approval in US
Teva Pharms USA Generic Lurasidone Hydrochloride Receives Approval in US